Uncomplicated Urinary Tract Infection Market Insight, Epidemiology and Market Forecast 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Uncomplicated Urinary Tract Infection – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Uncomplicated Urinary Tract Infection (uUTI) – Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the Uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Uncomplicated Urinary Tract Infection market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Uncomplicated Urinary Tract Infection Epidemiology

The Uncomplicated Urinary Tract Infection epidemiology division provides insights about the historical and current Uncomplicated Urinary Tract Infection patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total occurrence-specific cases of Uncomplicated Urinary Tract Infection was observed to be 35.3 million cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Uncomplicated Urinary Tract Infection epidemiology [segmented as Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection, Total Diagnosed Cases of Uncomplicated Urinary Tract Infection, Total Age-specific Cases of Uncomplicated Urinary Tract Infection, Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection, and Total Treated cases (across lines) of Uncomplicated Urinary Tract Infection] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Uncomplicated Urinary Tract Infection Drug Chapters

The drug chapter segment of the Uncomplicated Urinary Tract Infection report encloses the detailed analysis of Uncomplicated Urinary Tract Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Uncomplicated Urinary Tract Infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Uncomplicated Urinary Tract Infection Market Outlook

Urinary Tract Infection is an infection in any part of the urinary system, including kidneys, bladder, ureters, and urethra, which has been categorized into uncomplicated and complicated UTI. Uncomplicated Urinary Tract Infection typically affects individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. In contrast, complicated UTI is associated with factors that compromise the urinary tract or host defense, including urinary obstruction, immunosuppression, renal failure, renal transplantation, pregnancy, indwelling catheters, or other drainage devices.

Currently, antibiotics are still considered the gold standard of UTI treatments. Antibiotics are usually used to manage UTI because they reduce the duration and severity of symptoms and complications. The antimicrobial agents most commonly used to treat uUTI include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine.

Companies Mentioned

• GlaxoSmithKline
• Iterum Therapeutics
• Inmunotek
• Janssen Pharmaceuticals
• Fimbrion Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/3xyxhd

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900